Introduction {#s1}
============

Tuberculosis (TB), a deadly disease caused by the intracellular pathogen *Mtb,* has existed since time immemorial and continues to remain one of the leading causes of mortality by a single infectious agent ([@bib60]). Classic anti-TB therapy which comprises the administration of multiple anti-mycobacterial drugs, fails to provide complete sterilization in the host. Incessant rise in drug-resistant TB cases further highlights the failure of current anti-TB therapy which only focuses on targeting microbial pathways ([@bib60]). The host immune system plays a pivotal role in the containment of the infection, while *Mtb* has evolved diverse strategies to avoid immune surveillance facilitating its survival, replication, and persistence in the host ([@bib30]; [@bib40]). Our growing knowledge on host-pathogen interactions indicates that augmenting the current anti-TB therapy with host-directed strategies may result in enhanced bacterial clearance, shorter treatment times, reduced tissue damage, a decline in drug-resistant strains and a lower risk of relapse ([@bib47]).

For its enormous success as an intracellular pathogen, *Mtb* skews multiple host pathways in its favor. For example, *Mtb* is known to restrict the killing capacity of macrophages by inhibiting host generated oxidative stress, apoptosis and multiple stages of autophagy ([@bib33]; [@bib35]). It also influences the adaptive immune response by promoting the secretion of T helper 2 (Th2) polarizing cytokines ([@bib5]). Moreover, *Mtb* infection significantly changes the transcriptional landscape of host cells ([@bib51]) by secreting a plethora of virulence factors to carry out these functions. It also hijacks the function of several host genes for its gain ([@bib22]). Yet another mechanism has been uncovered recently ([@bib21]), wherein intracellular pathogens remodel the host chromatin for their persistence.

A balance between histone acetylation and deacetylation carried out by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively, play a crucial role in the regulation of gene expression. Till date, few bacteria have been reported to modulate the levels of acetylated histones. *Listeria monocytogenes*, a food-borne pathogen, dephosphorylates H3 and deacetylates H4 in epithelial cells through the action of a secreted virulence factor: listeriolysin O ([@bib20]). *Anaplasma phagocytophilium*, which causes human granulocytic anaplasmosis has been shown to activate the expression of HDAC1 and HDAC2 leading to transcriptional repression of key immunity genes ([@bib16]). The influence of *Mtb* infection on histone modifications and chromatin remodeling is still in its infancy. It has been shown that *Mtb* inhibits the expression of IFNγ-induced genes including CIITA, CD64, and HLA-DR through histone deacetylation ([@bib29]; [@bib54]). Moreover, broad-spectrum HDAC inhibitors enhance the anti-mycobacterial potential of host cells ([@bib42]).

The class III HDACs, or sirtuins (SIRT1-7) are homologous to the yeast Sir2 family of proteins and require NAD^+^ as a cofactor that links their enzymatic activity to the energy state of a cell. Thus far, very few studies have demonstrated the role of sirtuins in bacterial pathogenesis. Recent works emphasize the importance of SIRT1 and SIRT2 in the progression of bacterial infections ([@bib9]; [@bib12]; [@bib17]). Despite enhanced phagocytosis in SIRT2-deficient macrophages ([@bib10]), myeloid-specific SIRT2 deficiency fails to control *Mtb* growth in mice ([@bib7]).

SIRT2 primarily a cytoplasmic protein, is known to shuttle into the nucleus during mitosis ([@bib44]) where it regulates chromosome condensation. Mounting evidence suggests the role of SIRT2 in cell cycle regulation, tumorigenesis, neurodegeneration, cellular metabolism and energy homeostasis ([@bib18]).

In the present study, we attempt to decipher the role of SIRT2 in TB pathogenesis using chemical inhibition of SIRT2. We show that *Mtb* infection leads to upregulation and nuclear translocation of SIRT2 which induce consequential changes in histone acetylation, cellular signaling and transcriptional profile of the infected host macrophages and *Mtb*-stimulated T cells. Inhibition of SIRT2 activity restricted *Mtb* growth and reduced disease pathology in infected mice. SIRT2 inhibition triggered the induction of host protective immune responses, enhanced the efficacy of front-line anti-TB drug isoniazid (INH) and showed protection against drug-resistant strains. Thus, the study unravels a novel epigenetic mechanism employed by *Mtb* to recondition the host defense system, which can be exploited toward designing host-directed adjunct therapy.

Results {#s2}
=======

SIRT2 inhibition restricts *Mtb* growth ex vivo {#s2-1}
-----------------------------------------------

To delve into the epigenetic modifications induced by *Mtb* to evade host defence system, we evaluated the expression of all known HDACs in THP1 cells 24 hr post *Mtb* infection (pi) through microarray analysis ([@bib41]), Gene Expression Omnibus series accession number **GSE65714**. Among a total of 18 HDACs, SIRT2 and HDAC6 were significantly upregulated whilst SIRT1 and HDAC9 were downregulated ([Figure 1A](#fig1){ref-type="fig"}; [@bib41]). This is in accordance with a previous report indicating the *Mtb* mediated downregulation of SIRT1 ([@bib9]). The increase in the expression of SIRT2 following *Mtb* infection was further confirmed in mouse peritoneal macrophages by qRT-PCR ([Figure 1B](#fig1){ref-type="fig"}) and intracellular staining with α-SIRT2 followed by flow cytometry ([Figure 1C and D](#fig1){ref-type="fig"}). To uncover the biological relevance of *Mtb* mediated SIRT2 upregulation, we analyzed the intracellular survival of *Mtb* in peritoneal macrophages upon addition of AGK2, a well-established SIRT2 inhibitor ([@bib45]). Flow cytometric analysis of peritoneal macrophages infected with GFP expressing bacteria revealed significantly reduced *Mtb* growth ([Figure 1E](#fig1){ref-type="fig"}). Similarly, CFU enumeration indicated a significant reduction in the bacillary load upon AGK2 treatment ([Figure 1F](#fig1){ref-type="fig"}). Unlike Ciarlo et al, we did not observe any significant difference in the uptake of *Mtb* by macrophages treated with AGK2 ([Figure 1E and F](#fig1){ref-type="fig"}). To further ascertain the effects of SIRT2 downregulation on *Mtb* survival, we transfected RAW 264.7 macrophages with mouse shRNA-directed against SIRT2. Among the four shRNAs tested, shRNA three and shRNA five showed maximum downregulation of SIRT2 ([Figure 1G](#fig1){ref-type="fig"}). Similar to AGK2 treatment, bacterial survival was markedly attenuated in RAW 264.7 macrophages transfected with shRNA 3 and 5 ([Figure 1H and I](#fig1){ref-type="fig"}). SIRT2 is known to modulate the expression of antioxidant genes thereby influencing cellular redox homeostasis ([@bib18]). Furthermore, inhibition or downregulation of SIRT2 leads to the induction of apoptosis in many tumor cell lines ([@bib32]; [@bib64]). Since both apoptosis and ROS constitute one of the major innate defense strategies employed by macrophages against *Mtb* ([@bib2]) and SIRT2 has been previously shown to modulate the induction of apoptosis and intracellular ROS in different disease settings ([@bib61]), we analyzed these parameters upon SIRT2 inhibition during *Mtb* infection. While AGK2 treatment has minimal effect on uninfected macrophages ([Figure 1J and K](#fig1){ref-type="fig"}), its treatment significantly increased the percentage of apoptotic cells in *Mtb*-infected macrophages with a concomitant decrease in the necrotic population ([Figure 1L and M](#fig1){ref-type="fig"}). Interestingly AGK2 treatment also led to a significant increase in the intracellular ROS levels following *Mtb* infection with minimal effect on uninfected cells ([Figure 1N and O](#fig1){ref-type="fig"}). Moreover, treatment of cells with an anti-oxidant, N-acetyl cysteine ([@bib4]) significantly decreased the anti-mycobacterial effect of AGK2 ([Figure 1P--R](#fig1){ref-type="fig"}) indicating that ROS generation is one of the mechanisms by which SIRT2 inhibition restricts bacillary growth. Collectively, these results indicate a role for SIRT2 in assisting mycobacterial survival inside the host.

![SIRT2 aids in mycobacterial survival ex vivo.\
(**A**) Analysis of microarray data from [@bib41] reveals differential expression of SIRT1, SIRT2, HDAC6 and HDAC9 in THP1 cells 24 hr pi. FC: Fold Change in the gene expression in infected THP1 cells as compared to uninfected control, t: moderated t-statistics, B: B-statistics or log-odds that the gene is differentially expressed, adj.p.val: p-value after adjustment for multiple testing. (**B**) Mouse peritoneal macrophages were infected with *Mtb* laboratory strain *H37Rv* for 24 hr and SIRT2 expression was assessed through RT-PCR. (**C--D**) Mouse peritoneal macrophages infected with *Mtb* for 24 hr were stained with anti SIRT2 antibody followed by FACS analysis. (**E and F**) Mouse peritoneal macrophages, pre-treated with AGK2 for 2 hr, were infected with GFP expressing H37Rv and maintained in 10 µM of AGK2 for 48 hr. (**E**) Percentage of infected cells as analyzed by flow cytometry. (**F**) In a parallel experiment, cell lysates were plated for bacterial CFU at 0 hr and 48 hr pi. (**G--I**) RAW 264.7 macrophages were transfected with shRNAs specific for SIRT2. (**G**) 48 hr post transfection, SIRT2 protein levels were assessed by western blot. Transfected cells were infected with GFP expressing H37Rv for 48 hr. (**H**) Percentage of infected cells as analyzed by flow cytometry at 48 hr pi. (**I**) In a parallel experiment, cell lysate was plated for enumeration of CFU. (**J--M**) Representative dot plots and bar graphs to show the percentage of necrotic and apoptotic cell populations in the uninfected (**J and K**) and *Mtb* infected (**L and M**) peritoneal macrophages with or without AGK2 treatment as analyzed by FACS analysis. (**N and O**) Representative overlay plots and quantification of cellular ROS measured by staining cells with CellROX followed by flow cytometry. Mouse peritoneal macrophages treated with AGK2 (10 µM), NAC (10 mM) or both were infected H37Rv for 48 hr. (**P and Q**) Representative overlay plots and bar graph depicting cellular ROS in these cells 48 hr pi. (**R**) In a parallel experiment, cell lysates were plated for CFU enumeration. Data shown is representative of at least two independent experiments performed in triplicates. The data values represent mean ± SD (n = 3). \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005.\
Figure 1---source data 1.SIRT2 inhibition enhances anti-mycobacterial potential of host macrophages.Source data for [Figure 1B, D--F, H, I, K, M, O, Q and R](#fig1){ref-type="fig"}.](elife-55415-fig1){#fig1}

*Mtb* Infection triggers SIRT2 migration into the nucleus {#s2-2}
---------------------------------------------------------

SIRT2 predominantly resides in the cytoplasm where it targets cytosolic proteins to exert its functions. However, it is known to migrate to the nucleus during the G2/M transition and certain bacterial infections ([@bib12]; [@bib53]). To address whether similar translocation is promoted during *Mtb* infection, we determined the site of action of SIRT2 through immunofluorescence. Interestingly, while SIRT2 presence was observed in both the cytosol and the nucleus of uninfected macrophages, SIRT2 predominantly localized to the nucleus following *Mtb* infection as early as 4 hr pi ([Figure 2A](#fig2){ref-type="fig"}). SIRT2 migration into the nucleus was also confirmed by performing immunoblotting at 24 hr pi ([Figure 2B](#fig2){ref-type="fig"}). Significant increase in the overall expression of SIRT2 at protein level post *Mtb* infection correlated, with our qRT-PCR analysis ([Figures 1B](#fig1){ref-type="fig"} and [2B](#fig2){ref-type="fig"}). Since SIRT2 modulates the acetylation levels of histone H3K18 upon infection with *Listeria monocytogenes*, we analyzed H3K18 acetylation upon *Mtb* infection and AGK2 treatment in mouse peritoneal macrophages. AGK2 treatment had minimal effect on the acetylation levels of H3K18 in uninfected cells. However, there was a significant increase in H3K18ac levels in infected macrophages treated with AGK2, indicating that *Mtb*-induced nuclear localization of SIRT2 results in deacetylation of histone H3K18 ([Figure 2C and D](#fig2){ref-type="fig"}). α-tubulin is the major cytosolic target of SIRT2 which deacetylates it at lysine-40 to attenuate microtubule stability ([@bib43]). In order to evaluate the cytosolic activity of SIRT2, we checked the acetylation levels of α-tubulin following *Mtb* infection and upon SIRT2 inhibition. AGK2 treatment led to a comparable increase in the acetylated α-tubulin levels in uninfected and infected macrophages indicating the presence of cytosolic SIRT2 activity under both the conditions ([Figure 2E](#fig2){ref-type="fig"}). However, increased nuclear localization of SIRT2 after *Mtb* infection may contribute to the enhanced acetylated α-tubulin levels in the *Mtb* infected cells as compared to their uninfected counterparts ([Figure 2E](#fig2){ref-type="fig"}). SIRT2 modulates intracellular signaling by manipulating the activation of key Ser/Thr kinases in the host cells ([@bib26]; [@bib31]; [@bib37]). Thus we evaluated if SIRT2 inhibition had any impact on intracellular signaling. We measured the phosphorylation of ERK1/2 and p38 in peritoneal macrophages 2 hr after *Mtb* infection by immunoblotting. Interestingly, *Mtb* induced phosphorylation of ERK1/2 and p38 was decreased by AGK2 treatment ([Figure 2F](#fig2){ref-type="fig"}). Since SIRT2 inhibition strongly influenced the intracellular signaling and histone deacetylation, both of which ultimately lead to changes in cellular gene expression, we hypothesize that SIRT2 influences the intracellular *Mtb* growth by modulating the host gene expression.

![SIRT2 translocate to the nucleus and modulates histone deacetylations and cellular signaling during *Mtb* infection.\
(**A**) Endogenous SIRT2 was detected by immunofluorescence in mouse peritoneal macrophages uninfected or infected with *H37Rv* for 4 hr. (**B**) Uninfected macrophages or macrophages infected with H37Rv for 24 hr were fractionated for cytosol and nucleus followed by immunoblotting for the indicated proteins. Mouse peritoneal macrophages, pre-treated with AGK2 for 2 hr were infected *H37Rv* followed by AGK2 treatment for 24 hr. Acetylation levels of H3K18 were checked by (**C**) immunoblotting and (**D**) intracellular staining followed by flow cytometry. (**E**) Acetylated α-tubulin levels in uninfected and *Mtb*-infected cells with or without AGK2 treatment at 24 hr pi. (**F**) Mouse peritoneal macrophages, pre-treated with AGK2 for 2 hr were infected with *H37Rv* for 2 hr. Phosphorylation status of the indicated proteins was checked by immunoblotting. Data shown is representative of at least two independent experiments performed in triplicates. Each bar represents mean ± SD (n = 3). \*p\<0.05, \*\*p\<0.005.\
Figure 2---source data 1.SIRT2 migrates to the nucleus upon *Mtb* infection.Source data for [Figure 2B and D](#fig2){ref-type="fig"}.](elife-55415-fig2){#fig2}

SIRT2 induce global host gene expression changes during *Mtb* infection {#s2-3}
-----------------------------------------------------------------------

To further comprehend the underlying mechanisms involved in restricting *Mtb* growth upon SIRT2 inhibition, we carried out transcriptome analysis by performing RNAseq on uninfected and *Mtb*-infected peritoneal macrophages with and without AGK2 treatment (U: Uninfected macrophages, UA: Uninfected macrophages treated with AGK2; I: Macrophages infected with *Mtb*; IA: AGK2 treated infected macrophages). AGK2 treatment in uninfected cells did not alter the gene expression in a significant manner which is consistent with our earlier results wherein no effect on apoptosis, ROS levels, histone deacetylations and cellular signaling was observed in uninfected cells treated with AGK2 ([Figures 1K, O](#fig1){ref-type="fig"}, [2D and F](#fig2){ref-type="fig"}). In contrast, AGK2 treatment significantly affected the gene expression profile induced upon *Mtb* infection. In total, *Mtb* infection led to the differential expression of 992 genes which is in agreement with the previous findings ([@bib41]; [@bib51]). Genes that remained unaltered after AGK2 treatment were categorized as SIRT2 independent (414 genes) and the rest as SIRT2 dependent (578 genes) ([Figure 3A](#fig3){ref-type="fig"}). SIRT2-dependent genes can be further classified into six categories. Group 1: Decreased expression in I with no change in IA. Group 2: No change in expression in I and increased expression in IA. Group 3: Enhanced gene expression in IA as compared to I. Group 4: Decreased expression in IA with no change in I. Group 5: Increased expression in I with no change in IA. Group 6: Enhanced gene expression in I as compared to IA ([Figure 3A](#fig3){ref-type="fig"}). KEGG pathway analysis on SIRT2-dependent genes belonging to these groups (expect group 5) revealed that a significant number of pathways that are known to play a crucial role in combating TB were affected by AGK2 treatment ([Figure 3B](#fig3){ref-type="fig"}). For instance, genes involved in antigen presentation, Th17 cell differentiation, cytokine-cytokine receptor interaction, NF-κB signaling, tuberculosis, etc were significantly upregulated while PI3K/Akt signaling pathway was downregulated in SIRT2 inhibited samples ([Figure 3B](#fig3){ref-type="fig"}). Interestingly, the expression of genes involved in T cell activation was enhanced in SIRT2-dependent manner ([Figure 3C](#fig3){ref-type="fig"}). RNAseq data were validated by qRT-PCR of two genes from each group ([Figure 3D and E](#fig3){ref-type="fig"}). These results reiterate the existence of a novel anti-defense strategy employed by *Mtb* wherein it hijacks host SIRT2 to rewire the host transcriptional landscape for its survival.

![SIRT2 modulates host gene transcription during *Mtb* infection.\
(**A**) Heatmap interpretation of gene expression changes (Log2 fold) as determined by RNAseq analysis of peritoneal macrophages infected with *Mtb* for 24 hr. Pink depicts upregulation while blue represents repression. (**B**) KEGG analysis of molecular signaling pathways affected by AGK2 treatment. (**C**) Heatmap representing the expression profile of the genes involved in T cell activation. qRT-PCR of candidate genes which are either (**D**) up- or (**E**) downregulated in SIRT2 dependent manner. . U: Uninfected. UA: Uninfected treated with AGK2. I: Infected. IA: Infected with AGK2 treatment. RNAseq was performed in three biological replicates. Each bar in (**D**) and (**E**) represents mean ± SD (n = 3). \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005.\
Figure 3---source data 1.SIRT2 modulates transcriptional landscape of Mtb-infected macrophages.Source data for [Figure 3A and B--E](#fig3){ref-type="fig"}.](elife-55415-fig3){#fig3}

SIRT2 inhibition activates T-cell-mediated immunity via enhanced antigen presentation {#s2-4}
-------------------------------------------------------------------------------------

Our RNAseq data revealed SIRT2-dependent expression of many genes which drives the production of cytokines and activation of T cells ([Figure 3C](#fig3){ref-type="fig"}). Innate and adaptive immunity play a crucial role in shaping the disease outcome in case of TB. Previous studies have revealed the influence of SIRT2 on the production of pro-inflammatory cytokines ([@bib39]; [@bib62]). To replicate the in vivo conditions aimed at examining the effect on SIRT2 inhibition on the activation of macrophages and T cells, we performed co-culture experiments wherein splenocytes isolated from *Mtb* infected mice and peritoneal macrophages from naïve animals were either pre-treated separately with AGK2 prior to co-culture or infected peritoneal macrophages were co-cultured with splenocytes in the presence of AGK2 ([Figure 4A](#fig4){ref-type="fig"}). 48 hr post co-culture, the properties of macrophages and T cells were assessed by staining with antibodies against different surface markers and cytokines followed by FACS analysis. SIRT2 inhibition led to a marked increase in the expression of monocyte differentiation markers, CD11b and CD11c ([Figure 4B--D](#fig4){ref-type="fig"}). AGK2 treatment resulted in the increased expression of MHCII and CD80 co-stimulatory molecules which are known to stimulate T cells ([Figure 4B, E and F](#fig4){ref-type="fig"}). Interestingly, the expression of CD11b, CD11c and co-stimulatory markers CD80 and MHCII was significantly increased even in the condition where only the T cells were pre-treated with AGK2 ([Figure 4B--F](#fig4){ref-type="fig"}). With no change in the percentage of CD4^+^ T cells ([Figure 4G and H](#fig4){ref-type="fig"}), we observed an increase in their activation as evidenced by an increased expression of T cell activation markers CD69 and CD25 ([Figure 4I and J](#fig4){ref-type="fig"}). A similar trend was observed in CD8^+^ T cells ([Figure 4K--M](#fig4){ref-type="fig"}). Furthermore, SIRT2 inhibition increased the expression of pro-inflammatory cytokines IFNγ and IL17 by CD4^+^ and CD8^+^ T cells ([Figure 4N--Q](#fig4){ref-type="fig"}). However, SIRT2 inhibition in macrophage alone failed to drive strong Th1 and Th17 responses in CD4^+^ and CD8^+^ T cells while co-treatment of macrophages and T cells with AGK2 had a synergistic effect as IFNγ and IL17 production was significantly higher when splenocytes were co-cultured with macrophages in the presence of AGK2 ([Figure 4N--Q](#fig4){ref-type="fig"}). Similarly, the treatment of AGK2 in splenocytes alone or in both the cell types led to a significantly higher reduction in bacterial survival as compared to the SIRT2 inhibition in macrophages alone ([Figure 4R](#fig4){ref-type="fig"}). Overall, these results implicate a role for SIRT2 in modulating host protective T cell responses.

![SIRT2 inhibition activates macrophages and T cells to induce pro-inflammatory response.\
(**A**) Schematic representation of the experimental plan (for details see Materials and methods). 48 hr post co-culture, macrophages were stained with CD11b (APC/Cy7), CD11c (APC), CD80 (FITC) and MHC-II (PE) followed by flow cytometry analysis. (**B**) Gating strategy employed and representative overlay plots to depict macrophage activation. Expression of (**C**) CD11b, (**D**) CD11c, (**E**) CD80 and (**F**) MHCII on the surface of peritoneal macrophages. (**G**) Gating strategy for T cell activation. Splenocytes were stained for surface markers CD3 (Pacific Blue), CD4 (PE), CD8 (APC/Cy7), CD69 (FITC) and CD25 (APC) followed by flow cytometry. Percentage of (**H**) CD4^+^, (**I**) CD4^+^CD69^+^, (**J**) CD4^+^CD25^+^, (**K**) CD8^+^, (**L**) CD8^+^CD69^+^ and (**M**) CD8^+^CD25^+^ T cells. For cytokine analysis, splenocytes were stained with CD3 (Pacific Blue), CD4 (PE), CD8 (APC/Cy7), IFNγ (APC) and Il17 (PE/cy7). (**N and O**) Intracellular cytokines (IFNγ and IL17) expressed by CD4^+^ T cells. (**P and Q**) CD8^+^ T cells expressing IFNγ and IL17. (**R**) CFU at 48 hr post co-culture. Combined data from two independent experiments performed in triplicates is shown. Each bar represents mean ± SD (n = 6). Statistical analysis performed using one-way ANOVA followed by Tukey post hoc test. \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005.\
Figure 4---source data 1.SIRT2 inhibition leads to the activation of macrophages and T cells upon *Mtb* infection.Source data for [Figure 4C--F and H--R](#fig4){ref-type="fig"}.](elife-55415-fig4){#fig4}

SIRT2 deacetylates NFκB p65 in *Mtb*-specific T cells {#s2-5}
-----------------------------------------------------

The biological consequences of SIRT2 inhibition in T cells remain largely unexplored. In order to assess the SIRT2 activity in T cells, we isolated splenocytes from naive and *Mtb*-infected mice and stimulated them with *Mtb* complete soluble antigen (CSA) for 24 hr in the presence or absence of AGK2 ([Figure 5A](#fig5){ref-type="fig"}). Interestingly, we observed a significantly increased expression of SIRT2 in CD3^+^ lymphocytes isolated from the spleen of *Mtb*-infected animals ([Figure 5B and C](#fig5){ref-type="fig"}). Replicating the profile obtained in *Mtb*-infected macrophages, SIRT2 inhibition by AGK2 modulated the acetylation levels of H3K18 in these cells ([Figure 5D](#fig5){ref-type="fig"}). Furthermore, SIRT2 deacetylated NFκB p65 subunit at K310 in *Mtb*-specific CD3^+^ lymphocytes ([Figure 5E](#fig5){ref-type="fig"}).

![SIRT2 targets histone and non-histone proteins in *Mtb*-specific T-cells to ameliorate anti-mycobacterial host immune responses.\
(**A**) Schematic representation of the experimental plan. (**B**) Gating strategy utilized to analyze the intracellular levels of (**C**) SIRT2, (**D**) H3K18ac and (**E**) acetylated NFκB p65. Data shown is representative of at least two independent experiments each performed in triplicates. Data is represented as mean ± SD (n = 3). \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005.\
Figure 5---source data 1.SIRT2 deacetylates H3K18 and NFκB-p65 in *Mtb*-specific T cells.Source data for [Figure 5C, D and E](#fig5){ref-type="fig"}.](elife-55415-fig5){#fig5}

SIRT2 inhibition reduces the bacterial burden in mice {#s2-6}
-----------------------------------------------------

The ex vivo data encouraged us to replicate our findings in the host, towards which we infected a group of C57BL/6 mice with a low dose of *H37Rv* through aerosol. At 15 days pi, the mice were treated with AGK2 followed by an enumeration of bacterial burden and analysis of disease pathology at 45 days pi ([Figure 6A](#fig6){ref-type="fig"}). Histopathology analysis of infected lungs showed an overall decrease in lung inflammation after SIRT2 inhibition ([Figure 6B--D](#fig6){ref-type="fig"}). These data were further strengthened by the CFU analysis wherein the bacterial burden was significantly diminished in the lungs, spleen and liver of mice treated with AGK2 as compared with the control mice ([Figure 6E--G](#fig6){ref-type="fig"}). These results reiterated the inhibitory effects of SIRT2 deficiency on mycobacterial growth.

![SIRT2 inhibition restricts mycobacterial growth in vivo.\
(**A**) Schematic representation of the murine model of infection. A group of C57BL/6 mice were infected with low dose of *H37Rv*. After 15 days of disease establishment, mice were either left untreated or were treated with AGK2 (20 mg/kg) for 30 days. (**B**) Histopathological analysis of infected lungs with arrows indicating the granulomatous lesions. (**C and D**) Quantification of the number of granulomas (granuloma score) observed in the infected mice. (**E--G**) Bacterial load in the lungs, spleen and liver of mice at 45 days pi. (**H--J**) A group of *Rag1*^-/-^ mice were infected with low dose of H37Rv followed by treatment with AGK2 (20 mg/kg) for 30 days. The graphs represent bacterial burden in the lungs, spleen and liver of *Rag1*^-/-^ mice. E-J represents combined data from two independent experiments with four to five mice in each group. Granuloma score was obtained from the lungs of four mice per group. Data is represented as mean ± SD. \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005.\
Figure 6---source data 1.AGK2 treatment reduces bacterial burden in murine model of TB.Source data for [Figure 6D--J](#fig6){ref-type="fig"}.](elife-55415-fig6){#fig6}

In contrast to the previous report where myeloid-specific deletion of Sirt2 failed to display long-lasting changes in TB control ([@bib7]), administration of AGK2 significantly diminished the bacterial growth at early time points as well as at chronic late phase of infection. We speculate that the discrepancy in observed results is due to a fundamental difference between these two studies. While Cardoso et al used myeloid-specific Sirt2 KO mice, we employed the use of AGK2 which results in a more generic inhibition of SIRT2 activity thus emphasizing the importance of cells other than macrophages in containing *Mtb* infection. To corroborate our ex vivo results which emphasized the importance of SIRT2 inhibition in T cells for restricting intracellular *Mtb* growth, we performed infection experiments in *Rag1*^-/-^ mice that lack mature B and T cells. AGK2 treatment in these immunodeficient mice did not alter the bacterial survival as compared to the control group ([Figure 6H--J](#fig6){ref-type="fig"}) indicating that SIRT2 inhibition in T cells is indispensable in restricting *Mtb* growth inside the host.

AGK2 treatment activates host protective immune response against *Mtb* {#s2-7}
----------------------------------------------------------------------

The unrivalled ability of *Mtb* to survive within the host ensues from its strategies to evade the host immune defense system. Antigen-presenting cells (APCs) and Th1 cells are the key players contributing to the immunological control of *Mtb* infection. Encouraged by the results presented above, we profiled different immune cells in the lungs and the spleen of infected mice treated with AGK2 at 30 days post-treatment to fathom out the ability of AGK2 in modulating host protective adaptive immune responses for enhanced bacterial clearance. Increased percentage of CD11b^+^, CD11c^+^, CD80^+^ and MHCII^+^ cells, which are involved in the stimulation of adaptive immune responses, was observed in the lungs ([Figure 7A--E](#fig7){ref-type="fig"}) and the spleen of AGK2-treated mice (7F-7I). Similar to our ex vivo results, we observed an increased activation of CD4^+^ and CD8^+^ T cells in the lungs ([Figure 8A--G](#fig8){ref-type="fig"}) and the spleen ([Figure 8H--M](#fig8){ref-type="fig"}) of infected animals after AGK2 treatment. Moreover, the Th1 and Th17 bias in the immune response was evidenced by a prominent increase in the population of INFγ and IL17 producing CD4^+^ and CD8^+^ T cells in the lungs of AGK2-treated mice ([Figure 9A--E](#fig9){ref-type="fig"}). Interestingly, CD3^+^ cells isolated from the lungs of AGK2 treated and *Mtb*-infected mice displayed enhanced levels of NFκB p65 acetylation ([Figure 9F and G](#fig9){ref-type="fig"}). Upon SIRT2 inhibition, we observed a similar increase in the percentage of splenic CD4^+^ and CD8^+^ T cells producing pro-inflammatory cytokines IFNγ and IL17 ([Figure 9H--K](#fig9){ref-type="fig"}), indicating a shift in the immune balance toward Th1 and Th17 response. In summary, these data demonstrate the immunomodulatory effects of SIRT2 during *Mtb* infection.

![Inhibition of SIRT2 activity enhances macrophage stimulation in the lungs and spleen of infected animals.\
(**A**) After overnight stimulation with CSA, the cells isolated from the lungs of infected C57BL/6 animals were surface stained with CD11b (APC/Cy7), CD11c (APC), CD80 (FITC) and MHC-II (PE) followed by flow cytometry analysis. Gating strategy employed and flow cytometry dot plots of CD11b^+^CD80^+^, CD11b^+^MHCII^+^, CD11c^+^CD80^+^, CD11c^+^MHCII^+^ cells in the lungs of infected mice (**B--E**) Percentage of (**B**) CD11b^+^CD80^+^, (**C**) CD11b^+^MHCII^+^, (**D**) CD11c^+^CD80^+^ and (**E**) CD11c^+^MHCII^+^ cells in the lungs. (**F--I**) Percentage of CD11b^+^CD80^+^, CD11b^+^MHCII^+^, CD11c^+^CD80^+^, CD11c^+^MHCII^+^ cells in the spleen of infected mice. Data is representative of two independent experiments with five mice per group. Each graph represents mean ± SD (n = 5). \*\*\*p\<0.0005.\
Figure 7---source data 1.AGK2 treatment enhances macrophage stimulation in the lungs and spleen of infected animals.Source data for [Figure 7B--I](#fig7){ref-type="fig"}.](elife-55415-fig7){#fig7}

![SIRT2 inhibition ameliorates T cell activation in the lungs and spleen of infected mice.\
Cells isolated from the lungs of control and AGK2-treated *Mtb*-infected C57BL/6 animals were subjected to surface staining (CD3-Pacific Blue, CD4-PE, CD8-APC/Cy7, CD69-FITC and CD25-APC) followed by FACS analysis. (**A**) Gating strategy and representative dot plots. Scatter plots depicting the percentage of CD4^+^, CD4^+^CD69^+^, CD4^+^CD25^+^, CD8^+^, CD8^+^CD69^+^ and CD8^+^CD25^+^ T cells in the (**B--G**) lungs and the (**H--M**) spleen of infected mice. The experiment was performed twice with five mice in each group. Data is represented as mean ± SD (n = 5). \*\*p\<0.005, \*\*\*p\<0.0005.\
Figure 8---source data 1.SIRT2 inhibition increases T cell activation in vivo.Source data for [Figure 8B--M](#fig8){ref-type="fig"}.](elife-55415-fig8){#fig8}

![AGK2 treatment induces host protective immune responses against TB.\
Cells isolated from infected lungs of C57BL/6 mice were stained with CD3 (Pacific Blue), CD4 (PE), CD8 (APC/Cy7), IFNγ (APC) and IL17 (PE/cy7) followed by flow cytometry. (**A**) Gating strategy and representative flow cytometry dot plots. Percentage of IFNγ and IL17 producing CD4^+^ (**B and C**) and CD8^+^ (**D and E**) T cells in the lungs of infected mice. (**F**) Overlay plots and (**G**) quantification of acetylated NFκB p65 levels in the CD3^+^ T cells isolated from the lungs of infected mice. (**H--K**) IFNγ and IL17 expressing CD4^+^ (**H and I**) and CD8^+^ (**J and K**) T cells in the spleen of infected mice. The experiment was performed twice with five mice in each group. Data is represented as mean ± SD (n = 5). \*\*p\<0.005, \*\*\*p\<0.0005.\
Figure 9---source data 1.SIRT2 inhibition skews immune response toward Th1/Th17 phenotype Source data for [Figure 9B--D and G--K](#fig9){ref-type="fig"}.](elife-55415-fig9){#fig9}

T cells from SIRT2-deficient mice transfer protective immunity against *Mtb* {#s2-8}
----------------------------------------------------------------------------

To further demonstrate that protective immunity generated following AGK2 treatment was *Mtb* specific, we investigated whether adoptive transfer of T cells isolated from infected and AGK2-treated mice confer resistance to *Mtb* infection in naive mice. For this, we intravenously transferred one million CD4^+^ and CD8^+^ T cells isolated from the spleen of from infected and AGK2-treated mice into *Rag1*^-/-^ mice followed by low dose *Mtb* infection and CFU enumeration 21 days pi ([Figure 10A](#fig10){ref-type="fig"}). We first analyzed the overall health of these splenocytes by quantifying apoptosis and intracellular ROS. We observed that AGK2 treatment had no effect on the apoptotic levels in the splenic CD4^+^ and CD8^+^ T cells ([Figure 10B and C](#fig10){ref-type="fig"}). Similarly, ROS levels were also similar in the CD4^+^ and CD8^+^ T cells isolated from the spleen of infected and AGK2 treated animals ([Figure 10D and E](#fig10){ref-type="fig"}). To determine the bactericidal capacity of splenocytes, we performed co-culture experiments wherein GFP-H37Rv infected peritoneal macrophages were co-cultured with splenocytes isolated from the control or AGK2-treated infected mice for 48 hr followed by FACS analysis. Interestingly, mycobacterial growth was significantly restricted in macrophages co-cultured with T cells isolated from AGK2-treated mice ([Figure 10F](#fig10){ref-type="fig"}) indicating that AGK2 treatment enhances the efficacy of T cells in terms of stimulating macrophages for efficient bacterial clearance. Furthermore, T cells from AGK2-treated animals were more efficient in imparting protection to the *Rag1*^-/-^ mice as compared to the T cells from *Mtb*-infected mice (Cnt) ([Figure 10G and H](#fig10){ref-type="fig"}). These data signify the effector functions of adoptively transferred T cells, in enhancing anti-mycobacterial activity.

![AGK2-treated splenocytes demonstrate increased propensity toward mycobacterial killing and transfer *Mtb*-specific protective immunity in naive animals.\
(**A**) Schematic representation of the adoptive transfer experiment. Splenocytes isolated from infected and AGK2-treated C57BL/6 mice were analyzed for (**B and C**) apoptosis by Annexin V staining and (**D and E**) ROS production via cellROX (see Materials and methods). (**F**) Splenocytes isolated from infected and AGK2 treated mice were co-cultured with peritoneal macrophages infected with GFP expressing H37Rv. 48 hr pi, percentage of infected cells were analyzed by flow cytometry. CD4^+^ and CD8^+^ T cells purified from the spleen of infected and AGK2-treated mice (**G**) were intravenously transferred into *Rag1*^-/-^ mice followed by challenge with aerosolized *Mtb*. (**H**) CFU enumeration 21 days after adoptive transfer. Data is representative of two independent experiments performed with four to five mice in each group. Data is represented as mean ± SD (n = 5). H shows combined data from two independent experiments (n = 9). \*p\<0.05, \*\*\*p\<0.0005.\
Figure 10---source data 1.AGK2-treated splenocytes transfer *Mtb*-specific protective immunity in naive animals.Source data for [Figure 10C, E, F and H](#fig10){ref-type="fig"}.](elife-55415-fig10){#fig10}

AGK2 as an adjunct therapy against susceptible and drug-resistant tuberculosis {#s2-9}
------------------------------------------------------------------------------

In terms of TB pathology, both the C57BL/6 and BALB/c exhibit similar resistant phenotype to infections ([@bib27]). In order to reinforce the protective effects of AGK2, we repeated in vivo infections in BALB/c mice ([Figure 11A](#fig11){ref-type="fig"}). AGK2 treatment significantly lowered the bacterial load in the lungs ([Figure 11B](#fig11){ref-type="fig"}), spleen ([Figure 11C](#fig11){ref-type="fig"}) and liver ([Figure 11D](#fig11){ref-type="fig"}) of infected animals as compared to the control group. Lastly, to examine the efficacy of AGK2 as an adjunct to anti-TB therapy we designed a combinatorial therapy wherein infected mice were treated with a combination of AGK2 and front line anti-TB drug INH for 15 days followed by CFU enumeration ([Figure 11E](#fig11){ref-type="fig"}). Co-treatment of AGK2 and INH significantly decreased the bacterial burden in the lungs as compared to the mice treated with either AGK2 or INH alone ([Figure 11F](#fig11){ref-type="fig"}). Interestingly, AGK2 treatment significantly decreased the bacillary load of MDR as well as XDR strains of TB ([Figure 11G--I](#fig11){ref-type="fig"}). One of the advantages of host-directed therapies (HDTs) is the reduction in the risk of generation of drug resistance. HDTs provide untapped opportunities to eliminate drug-resistant strains by manipulating host immune system.

![AGK2 treatment increases the efficacy of anti-TB drug INH.\
(**A**) Experimental plan for infection in BALB/c mice. (**B--D**) CFU enumeration to determine the bacterial burden in the lungs, spleen and liver of infected mice. (**E**) Schematic representation of the adjunct therapy experiment. A group of mice were infected with low dose of *H37Rv*. Following a rest of 15 days, mice were either left untreated or were treated with AGK2, INH or both. After 15 days of treatment, mice were euthanized for CFU enumeration in the lungs. (**F**) CFU from the lung homogenates of respective animals. (**G**) Schematic representation of the AGK2 treatment infection model. (**H and I**) CFU obtained from the lung homogenates of mice infected with MDR and XDR strains of *Mtb* with and without AGK2 treatment. The experiment was performed once with five mice in each group. Data is represented as mean ± SD (n = 5). \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005.\
Figure 11---source data 1.Efficacy of AGK2 as an adjunct to current anti-TB drug INH.Source data for [Figure 11B--D, F, H and I](#fig11){ref-type="fig"}.](elife-55415-fig11){#fig11}

Discussion {#s3}
==========

To combat host-induced stresses, *Mtb* has evolved several survival strategies. Recent studies hint toward the pathogen-induced histone modifications as an emerging host subversion strategy employed by a number of bacteria and viruses for successful persistence inside the host. Virulence factors and toxins released by the pathogens have been shown to alter host epigenome by modulating the activity of HATs and HDACs. *Mtb* was shown to induce histone deacetylation at the HLA-DRα promoter leading to the inhibition of IFN-γ-dependent HLA-DR gene expression ([@bib54]). Since this study, many pathogens were shown to influence host histone acetylome ([@bib19]). For instance, virulence factor listeriolysin-O (LLO) of *L. monocytogenes* causes global histone H4 deacetylation, whereas invasin protein InlB mediates histone H3K18 deacetylation both of which lead to transcriptional reprograming of the host ([@bib12]; [@bib20]). Upregulation of HDACs by intracellular pathogens like *Anaplasma phagocytophilum*, *Pseudomonas aeruginosa*, *Porphyromonas gingivalis* led to epigenetic suppression of host defense genes. Lately, pathogens were shown to target sirtuins for subverting host acetylome. *Salmonella typhimurium* degrades SIRT1 to evade autophagy ([@bib15]) while it upregulates SIRT2 to regulate NOS2 activity ([@bib17]). Recently, it was shown that activation of SIRT1 aids *Mtb* survival by inducing phagosome-lysosome fusion and autophagy ([@bib9]). In this study, we for the first time show significant upregulation of SIRT2 during *Mtb* infection in peritoneal macrophages. Inhibition of SIRT2 activity by AGK2 as well as a decrease in the SIRT2 levels following siRNA treatment led to decreased intracellular survival of *Mtb*.

APCs play a critical role in TB pathogenesis by directly killing the bacteria and by activating T cells and thus shaping the extent and nature of the adaptive immune response. Expression and engagement of MHC and costimulatory molecules on the surface of APCs activates these cells as well as T cells leading to the release of pro-inflammatory cytokines such as IFNγ and IL17 which are shown to play a protective role in TB disease. IFNγ deficiency in humans and mice is associated with increased susceptibility to *Mtb *([@bib13]; [@bib63]). Apart from being a protective cytokine, IL17 is also essential for recall responses to *Mtb*([@bib8]). SIRT2 has been shown to inhibit the stress-induced expression of pro-inflammatory cytokines and surface activation markers in different cell lines ([@bib28]; [@bib39]; [@bib46]). In our study, AGK2 treatment increased the expression of activation markers on the surface of mouse peritoneal macrophages upon *Mtb* infection leading to a prominent T cell activation and elevated levels of proinflammatory cytokines. A similar effect of SIRT2 inhibition was observed in *Mtb* specific T cells wherein AGK2 treatment led to enhanced acetylation of histone H3K18 and NFκB p65 leading to the induction of proinflammatory genes ([@bib9]). For the first time, we demonstrate that SIRT2 inhibition in T cells shifts the type-1/type-2 balance toward protective Th1/Th17 response during TB pathogenesis.

The protective role of SIRT2 deficiency has been well documented in age-related neurodegenerative diseases ([@bib14]). However, very few studies talk about SIRT2 dependent disease progression in bacterial and viral infections ([@bib10]; [@bib17]; [@bib48]). As a well-established SIRT2 inhibitor, several studies have used AGK2 treatment in mice models with no visible side effects ([@bib57]). Consequently, we extended our study in the murine model of TB. Mice administered with AGK2 displayed a significant reduction in bacterial load, which translated into diminished tissue pathology evident by the negligible presence of granulomatous lesions in the lungs. Innate cytokine milieu induced by SIRT2 inhibition drive the adaptive immune response toward Th1 and Th17 cells. Cytokine profiling indicated a robust pro-inflammatory response in the lungs and the spleen of AGK2 treated and *Mtb*-infected mice. SIRT2 has been shown to regulate immuno-metabolism in sepsis ([@bib59]). SIRT2 inhibits inflammatory response in obese mice via deacetylating NFĸB p65 ([@bib58]). Treatment of SIRT2 specific inhibitor AK7 enhanced LPS-induced pro-inflammatory cytokine response in RAW 264.7 macrophages ([@bib58]). *Mtb* upregulates the expression of IL-10 via TLR2-ERK pathway to promote TB pathogenesis ([@bib1]; [@bib49]). Interestingly, AGK2 treatment decreases the phosphorylation of ERK1/2 in peritoneal macrophages. Furthermore, previous reports suggest that high SIRT2 expression is associated with upregulation of IL-10 ([@bib11]; [@bib39]). The immune response generated during AGK2 treatment was *Mtb* specific as was evident by adoptive transfer studies wherein T cells from AGK2 treated and *Mtb* infected mice when transferred into naive *Rag1*^-/-^ mice conferred resistance to *Mtb* infection. Moreover, splenocytes from mice treated with AGK2 displayed a higher ability to promote *Mtb* killing by macrophages. In mycobacterial infections, apoptosis of infected macrophages is thought to prevent bacterial spread and restrict mycobacterial growth by inducing host immune response ([@bib52]). However, apoptosis of T cells results in T cell exhaustion and is correlated with defective immune response. Noteworthy is the fact that SIRT2 deficiency resulted in increased apoptosis in peritoneal macrophages with no effect on T cells which is in agreement with earlier reports demonstrating the anti-apoptotic effects of SIRT2 in macrophages ([@bib36]; [@bib65]).

SIRT2 is mainly considered to be active in the cytosol where it targets many cellular proteins to regulate multiple pathways such as microtubule dynamics (α-tubulin, \[[@bib43]\], adipogenesis (FOXO1, \[[@bib26]\], mitochondrial biogenesis (PGC-1α, \[[@bib34]\], metabolism (ACLY, PEPCK1, G6PD, \[[@bib25]; [@bib38]; [@bib56]\], ROS suppression (FOXO3a, \[[@bib55]\], inflammation (NF-κB, \[[@bib50]\] and many more \[[@bib18]\]. However, SIRT2 has also been shown to transiently shuttle to the nucleus under certain conditions where it targets both histone and non-histone proteins. It regulates mitosis by deacetylating H4K16 and DNA-damage induced hyper-acetylation by targeting P300 and H3K56 ([@bib23]). Recently, Eskandarian et al uncovered a novel nuclear function of SIRT2 where it regulates host gene expression by deacetylating H3K18 during *Listeria* infection. Our data also suggests nuclear migration of SIRT2 upon *Mtb* infection where it deacetylates H3K18 to influence gene expression. In line with the above observations, our RNAseq data revealed a similar trend where AGK2 treatment did not influence the gene expression pattern of uninfected macrophages, whereas out of 992 total genes affected by *Mtb* infection, the expression of more than 50% (578) of the genes was dependent on SIRT2 activity. KEGG pathway analysis performed on SIRT2-dependent genes revealed a significant number of pathways, which have a known role to play in the containment of *Mtb* infection. For instance, there was a significant up-regulation in genes involved in antigen processing and presentation, Th17 cell differentiation, cytokine-cytokine receptor interactions and TNF signaling.

*Mtb* infection results in the phosphorylation of PI3K and Akt while inhibiting the activity of either PI3K or Akt leads to the suppression of mycobacterial growth in the host cell via upregulation of matrix metalloproteinases and multiple pro-inflammatory cytokines ([@bib6]; [@bib24]). Interestingly, PI3K-Akt signaling and TLR signaling pathways were downregulated upon AGK2 treatment.

Although antimicrobial effects of SIRT2 inhibition have been demonstrated in *Salmonella* and *Listeria*, this is the first report suggesting modulation of host adaptive immune responses as one of the mechanisms by which AGK2 inhibits the growth of an intracellular pathogen. These data are further strengthened by our transcriptome studies which provide an insight into the mechanistic details of how SIRT2 activity aids in mycobacterial survival. The proposed mechanism of mycobacterial restriction via AGK2 is depicted in [Figure 12](#fig12){ref-type="fig"}.

![Proposed mechanism of SIRT2 up-regulation and consequence of SIRT2 inhibition on *Mtb* survival.\
(**A**) *Mtb* infection induces the expression and translocation of SIRT2 in the nucleus where it deacetylates histone H3K18 to induce consequential changes in host transcriptome leading to decreased activation of macrophages, reduced levels of apoptosis and ROS, and increased expression of anti-inflammatory Th2-polarizing cytokines. Simultaneously, upregulation of SIRT2 in *Mtb-*specific T-cells specifically deacetylates and deactivates NFκB p65 leading to an anti-inflammatory response. M2 macrophages and Th2 cells preferentially generated provide a more favorable environment for *Mtb* survival within the host. (**B**) SIRT2 inhibition in *Mtb*-infected cells reverses the SIRT2-dependent gene expression changes enhancing the capacity of macrophages to activate T-cells. AGK2 treatment also enhances anti-mycobacterial defense forces in macrophages such as apoptosis, ROS and pro-inflammatory Th1/Th17 polarizing cytokines. Moreover, hyperacetylation of NFκB p65 in *Mtb*-specific activated T-cells leads to Th1/Th17-mediated pro-inflammatory immune response. Enhanced levels of protective innate and adaptive immunity in AGK2 treated cells restrict mycobacterial survival.](elife-55415-fig12){#fig12}

With this background we attempted to put forth SIRT2 inhibitors as potential candidates for HDTs in adjunct with the existing anti-TB regime and to our satisfaction, AGK2 was successful in further reducing the bacillary load in INH-treated infected mice. However, further studies on different experimental models such as non-human primates and with a series of other chemical inhibitors of SIRT2 are required to fully explore the usability of SIRT2 inhibitors as potential TB HTDs. Nevertheless, the ability of AGK2 to effectively target drug-resistant strains of *Mtb* is an encouraging finding towards the development of newer TB therapeutics.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                     Designation                                                    Source or reference                                           Identifiers                                                              Additional information
  (species) or resource                                                                                                                                                                                                                   
  --------------------------------- -------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------
  Genetic reagent (*M. musculus*)   *B6.129S7-Rag1^tm1Mom^/J*                                      PMID:[1547488](https://www.ncbi.nlm.nih.gov/pubmed/1547488)   RRID:[IMSR_JAX:002216](https://scicrunch.org/resolver/IMSR_JAX:002216)   

  Cell line (*M. musculus*)         RAW 264.7                                                      ATCC                                                          RRID:[CVCL_0493](https://scicrunch.org/resolver/CVCL_0493)               

  Antibody                          Rabbit monoclonal \[EP959Y\] to Histone H3 (acetyl K18)        Abcam                                                         Cat\#ab40888                                                             1:10000 (WB)\
                                                                                                                                                                                                                                          1:2000 (FC)

  Antibody                          Rabbit polyclonal to NF-kB p65 (acetyl K310)                   Abcam                                                         Cat\#ab19870                                                             1:5000 (WB)\
                                                                                                                                                                                                                                          1:1000 (FC)

  Antibody                          Rabbit polyclonal to beta Actin                                Abcam                                                         Cat\#ab8227                                                              1:5000 (WB)\

  Antibody                          Mouse monoclonal \[GT114\] to alpha Tubulin                    Abcam                                                         Cat\#ab184613                                                            1:5000 (WB)\

  Antibody                          Rabbit monoclonal \[EPR16772\] to alpha Tubulin (acetyl K40)   Abcam                                                         Cat\#ab179484                                                            1:2500 (WB)\
                                                                                                                                                                                                                                          1:1000 (FC)

  Antibody                          Rabbit monoclonal \[EPR20411\] to SIRT2                        Abcam                                                         Cat\#ab211033                                                            1:2500 (WB)\
                                                                                                                                                                                                                                          1:1000 (FC)

  Antibody                          FITC anti-mouse CD4 Antibody                                   Biolegend                                                     Cat\#100510                                                              1:250 (FC)

  Antibody                          PerCP anti-mouse CD4 Antibody                                  Biolegend                                                     Cat\#100433                                                              1:250 (FC)

  Antibody                          APC anti-mouse CD4 Antibody                                    Biolegend                                                     Cat\#100411                                                              1:250 (FC)

  Antibody                          APC/Cyanine7 anti-mouse CD8a Antibody                          Biolegend                                                     Cat\#100713                                                              1:250 (FC)

  Antibody                          FITC anti-mouse CD69 Antibody                                  Biolegend                                                     Cat\#104506                                                              1:250 (FC)

  Antibody                          APC anti-mouse CD25 Antibody                                   Biolegend                                                     Cat\#101910                                                              1:250 (FC)

  Antibody                          APC/Cy7 anti-mouse/human CD11b Antibody                        Biolegend                                                     Cat\#101226                                                              1:250 (FC)

  Antibody                          APC anti-mouse CD11c Antibody                                  Biolegend                                                     Cat\#117310                                                              1:250 (FC)

  Antibody                          APC anti-mouse IFN-γ Antibody                                  Biolegend                                                     Cat\#505810                                                              1:250 (FC)

  Antibody                          PE/Cyanine7 anti-mouse IL-17A Antibody                         Biolegend                                                     Cat\#506922                                                              1:250 (FC)

  Antibody                          PE anti-mouse CD4 Antibody                                     Biolegend                                                     Cat\#100512                                                              1:250 (FC)

  Antibody                          FITC anti-mouse CD80 Antibody                                  Biolegend                                                     Cat\#104706                                                              1:250 (FC)

  Antibody                          PE anti-mouse I-A/I-E Antibody                                 Biolegend                                                     Cat\#107607                                                              1:250 (FC)

  Antibody                          Pacific Blue anti-mouse CD3 Antibody                           Biolegend                                                     Cat\#100214                                                              1:250 (FC)

  Antibody                          p44/42 MAPK (Erk1/2) Antibody                                  Cell Signaling Technology                                     Cat\#9102                                                                1:2000 (WB)

  Antibody                          Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) Antibody          Cell Signaling Technology                                     Cat\#9101                                                                1:1000 (WB)

  Antibody                          p38 MAPK Antibody                                              Cell Signaling Technology                                     Cat\#9212                                                                1:2000 (WB)

  Antibody                          Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP Rabbit mAb          Cell Signaling Technology                                     Cat\#4511                                                                1:1000 (WB)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

BALB/c, C57BL/6 and *Rag1*^-/-^(6--8 weeks of age) female mice were procured from NII, New Delhi, India. All animals were maintained in the animal facility of NII, New Delhi, India.

Bacteria {#s4-2}
--------

The mycobacterial strains used in this study (H37Rv, MDR and XDR) were maintained in 7H9 (Middlebrook, Difco) medium supplemented with 10% ADC (albumin, dextrose, and catalase; Difco), 0.05% Tween 80% and 0.2% glycerol. Cultures grown to mid-log phase were preserved in 20% glycerol at −80°C. Infections were carried out from these cryopreserved stocks.

Peritoneal macrophages {#s4-3}
----------------------

Two ml of 4% thioglycollate (Sigma) was injected into C57BL/6 mice intraperitoneally. Five days later, peritoneal cavity was washed with ice cold PBS in order to extract peritoneal exudates cells. These cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (Thermo fisher scientific Inc or Hyclone). After overnight incubation at 37°C and 5% CO~2~, cells were washed with PBS to remove non-adherent cells. Adherent monolayer cells were confirmed to be pure macrophages by staining with CD11b antibody followed by flow cytometry (FACS Verse Cell-Sorting System, BD Biosciences). FACS Data was analyzed using the FACSuite software (BD Biosciences).

AGK2 treatment {#s4-4}
--------------

The peritoneal macrophages were pre-treated with 10 µM of AGK2 for 2 hr following infection with *Mtb* at an MOI of 10. 4 hr after infection, the cells were washed twice with 1X PBS to remove the extracellular bacilli. The infected cells were then maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum along with 10 µM of AGK2 throughout the course of the experiment.

Transfection shRNA transfections were carried out in RAW 264.7 macrophages (no mycoplasma contamination) seeded in 12-well plates at the density of 0.5 × 10^6^ cells per well using Lipofectamine 2000 Transfection Reagent (Invitrogen) as per manufacturer\'s instructions ([@bib3]). 24 hr post transfection, cells were infected with GFP expressing H37Rv for 4 hr. After washing twice with PBS to remove extracellular bacilli, cells were incubated in a 5% CO~2~ incubator at 37°C for 48 hr followed by flow cytometry in order to detect intracellular bacterial fluorescence (MFI) and percentage of infected cells. Cell lysates were also plated onto 7H11 plates for CFU enumeration.

Bacterial infections and co-culture of macrophages with T cells {#s4-5}
---------------------------------------------------------------

Peritoneal macrophages were cultured at the density of 1 × 10^6^ cells per ml of media. Cells were infected with *Mtb* H37Rv (MOI 10). For infection, cryostocks of bacteria were resuspended in 1 ml PBS and passed through 26-gauge needles five times in order to achieve single-cell suspensions. For co-culture experiments, the spleen from infected animals were harvested and single-cell suspensions were made using frosted glass slides followed by RBC lysis. Cells were counted and seeded with the macrophages in a ratio of 1:10. After 48 hr, macrophages and splenocytes were screened for different surface markers and intracellular cytokines by flow cytometry.

Fluorescent microscopy {#s4-6}
----------------------

Peritoneal macrophages were plated on cover slips and infected with H37Rv-GFP at an MOI of 10. After 4hof infection, cells were fixed with 4% paraformaldehyde and permeabilized with 0.2% (w/v) Triton X-100 in PBS for 20 min. This was followed by primary (SIRT2, Abcam) and secondary (alexa594, CST) antibody staining as per the manufacturer's instructions. After washing thoroughly with PBS, the cover slips were mounted onto glass slides with DAPI containing Vectashield mountant (H-1200, Vector Labs). Several fields were acquired randomly from each set with a Carl Zeiss epifluoresence microscope. Images were saved as 16-bit TIF files and analyzed by ImageJ software (<http://rsb.info.nih.gov/ij/>).

Western blot analysis {#s4-7}
---------------------

RIPA buffer (50 mM Tris,pH 8.0, 150 mM NaCl, 1.0% NP-40, 0.5% Sodium deoxycholate, 0.1% SDS) freshly supplemented with PhosSTOP and complete protease inhibitor procured from Roche was used to prepare whole cell lysates of peritoneal macrophages. Samples were electrophoresed on SDS-PAGE and electroblotted onto nitrocellulose membranes (Bio-Rad). After blocking with 5% BSA prepared in PBST (PBS and 0.05% Tween-20), blots were probed for different proteins using corresponding antibodies acquired from Abcam and CST. Blots were developed on autoradiograms using chemiluminescent HRP substrate (ECL, Millipore). Histones were extracted using histone extraction kit from Abcam, USA as per manufacturer's details. Cell lysates were fractionated into cytosolic and nuclear fractions using nuclear extraction kit from Abcam, USA according to the protocol provided by the manufacturer.

qPCR analysis {#s4-8}
-------------

Total RNA was isolated from peritoneal macrophages either uninfected or infected with H37Rv with and without AGK2 treatment using RNAeasy isolation kit (QIAGEN, Germany) according to the manufacturer's instructions. cDNA was synthesized using iscript cDNA synthesis kit (Bio-Rad) followed by qRT-PCR using SYBR Green Master Mix (Bio-Rad). Real-time quantitative RT-PCR analysis was performed using BioRad Real-Time thermal cycler (BioRad, USA). The primers used in the study are:

PrimerSequence (5\'−3\')*H2-Aa* Forward PrimerTCAGTCGCAGACGGTGTTTAT*H2-Aa* Reverse PrimerGGGGGCTGGAATCTCAGGT*CD74* Forward PrimerCCGCCTAGACAAGCTGACC*CD74* Reverse PrimerACAGGTTTGGCAGATTTCGGA*IL22* Forward PrimerATGAGTTTTTCCCTTATGGGGAC*IL22* Reverse PrimerGCTGGAAGTTGGACACCTCAA*CD14* Forward PrimerCTCTGTCCTTAAAGCGGCTTAC*CD14* Reverse PrimerGTTGCGGAGGTTCAAGATGTT*CCL7* Forward PrimerGCTGCTTTCAGCATCCAAGTG*CCL7* Reverse PrimerCCAGGGACACCGACTACTG*CXCL1* Forward PrimerCAAGGCTGGTCCATGCTCCCCL7 Reverse PrimerTGCTATCACTTCCTTTCTGTTGCGNG7 Forward PrimerTCAGGTACTAACAACGTCGCCGNG7 Reverse PrimerCAGTAGCCCATCAGGTCTGAC*ITGA3* Forward PrimerCCTCTTCGGCTACTCGGTCGNG7 Reverse PrimerCCGGTTGGTATAGTCATCACCC*STAT1* Forward PrimerTCACAGTGGTTCGAGCTTCAG*STAT1* Reverse PrimerGCAAACGAGACATCATAGGCA*CREB5* Forward PrimerAGGATCTTCTGCCGTCTTGAT*CREB5* Reverse PrimerGCGCAGCCTTCAGTCTCAT*IL6* Forward PrimerTGGGGCTCTTCAAAAGCTCC*IL6* Reverse PrimerAGGAACTATCACCGGATCTTCAA*ZBP1* Forward PrimerAAGAGTCCCCTGCGATTATTTG*ZBP1* Reverse PrimerTCTGGATGGCGTTTGAATTGG*SIRT2* Forward PrimerGAGGTGGCATGGATTTTGAC*SIRT2* Reverse PrimerAGATGGTAGTGCTGGGGTTG*ΑCTB* Forward PrimerAGTGTGACGTTGACATCCGTAAAGA*ΑCTB* Reverse PrimerGGACAGTGAGGCCAGGATGG

RNAseq analysis {#s4-9}
---------------

Mouse peritoneal macrophages were infected with *Mtb* at an MOI of 10 and harvested 24 hr pi for RNA isolation. RNAseq was carried out by Macrogen, Inc in collaboration with Bencos Research Solutions Pvt. Ltd. for data analysis. Briefly, the methodology included generation of raw sequencing reads followed by adapter trimming and QC filtering of reads:Phred score (Q) \> 30, alignment to reference genome (mapped unique reads \>80%), normalization and read count generation and finally differential expression determined using DESeq2 (significant differentially expressed genes selected based on FDR \< 0.05). The quality assessment was carried out on raw Fastq files received using NGS QC toolkit with a minimum average quality (Q) value of 20 and an overall cutoff of 70%. Filtered reads were aligned with STAR alignment tool. GRCm38 was used as a reference genome. HTSeq was used to quantify the reads for all genes. After quantification, DESeq2 was used for differential gene expression analysis. GO enrichment was carried out using the R bioconductor package 'ClusterProfiler'.

*Mtb* infection of mice and enumeration of colony forming units (CFU) {#s4-10}
---------------------------------------------------------------------

Mice were infected with *Mtb* via the aerosol route using a Madison aerosol chamber (University of Wisconsin, Madison, WI) with its nebulizer pre-calibrated to deposit a total of \~110 to the lungs of each mouse as previously described ([@bib5]). Briefly, mycobacterial stocks recovered from a −80°C freezer were quickly thawed and passed through 26 gauge syringe five times to obtain a single-cell suspension. Fifteen ml of the bacterial cell suspension (1.5 × 10^6^ cells per ml) was placed in the nebulizer of the Madison aerosol chamber. Five randomly selected mice were sacrificed at various time points and organs were harvested, homogenized in 0.2 µm filtered PBS containing 0.05% Tween 80, plated onto 7H11 Middlebrooks (Difco USA) plates containing 10% oleic acid, albumin, dextrose and catalase (OADC) (Difco, USA) and incubated at 37°C for 21--28 days. Bacterial colonies were counted and CFU were estimated as per dilution. Half the spleen and the lung from each mouse was used for immune cell profiling.

Drug administration {#s4-11}
-------------------

For ex vivo experiments, peritoneal macrophages were treated with 10 µM AGK2. 20 mg/kg of SIRT-2 inhibitor (AGK2, Abcam) in 100 μl of PBS containing 5% DMSO v/v was administered intraperitoneally to the mice thrice a week for 45 days, whereas control mice were given vehicle only. INH (100 mg/L) was constantly present in the drinking water of treated animals. The water was changed every second or third day.

Flow cytometry: surface and intracellular staining {#s4-12}
--------------------------------------------------

Ex vivo: Splenocytes and macrophages from co-culture experiments were taken out and stained for different surface markers and intracellular cytokines. Briefly, macrophages were surface stained with CD11b (APC/Cy7), CD11c (APC), CD80 (FITC) and MHC-II (PE). Splenocytes were surface stained with CD3 (Pacific Blue), CD4 (PE), CD8 (APC/Cy7), CD69 (FITC) and CD25 (APC). For intracellular cytokine analysis, splenocytes were stained with CD3 (Pacific Blue), CD4 (PE), CD8 (APC/Cy7), IFNγ (APC) and IL17 (PE/cy7).

In vivo: The lungs and the spleen were isolated from mice and macerated by frosted slides in ice cold RPMI 1640 containing 10% FBS to prepare single-cell suspension. Red blood cells (RBCs) were lysed with RBC cell lysis buffer and cells were washed with 10% RPMI 1640. 1 × 10^6^ cells per surface marker were used for surface staining. For intracellular staining, 1 × 10^6^ cells were cultured per well in 12-well plates, activated with H37Rv Complete Soluble Antigen o/n, followed by treatment with 10 μg/ml Brefeldin A (eBiosciences, USA) for 6 hr. Cells were washed twice with PBS and stained with fluorescently labeled antibodies directed against surface markers. After staining, cells were washed again with PBS and fixed with 100 μl fixation buffer (eBiosciences, USA) for 30 min, then re-suspended in 200 μl permeabilization buffer (eBiosciences, USA) and stained with fluorescently labeled anti-cytokine antibodies. For detecting the levels of SIRT2, histone H3K18ac, acetylated NFκB p65 and acetylated α-tubulin, permeabilized cells were stained with appropriate primary antibodies followed by staining with secondary antibody labeled with Alexa Fluor 647 or isotype control IgG-APC. The intensity of fluorochrome-labeled cells was measured by flow cytometry (FACS Verse Cell-Sorting System, BD Biosciences). Data analysis was performed by FlowJo (Tree star, USA).

T cell adoptive transfer {#s4-13}
------------------------

The spleen from infected and AGK2 treated animals were harvested and single-cell suspensions were made using frosted glass slides followed by RBC lysis. Cells stained with the anti-CD4 and anti-CD8 antibodies were sorted into CD4^+^ and CD8^+^ pure population in FACS Aria (BD Biosciences) and cultured overnight in complete RPMI medium. One million of pooled CD4^+^ and CD8^+^ T cells were transferred intravenously into *Rag1*^-/-^ mouse. Two days later, the mice were infected with low dose infection with aerosolized *Mtb*.

Apoptosis and cellular ROS {#s4-14}
--------------------------

Peritoneal macrophages or splenocytes isolated from infected animals were analyzed for apoptosis with the help of FITC annexin V apoptosis detection kit with 7-AAD from Biolegend as per the manufacturer's protocol. Cellular ROS levels were detected by staining the cells with CellROX Deep Red Reagent, ThermoFisher Scientific followed by flow cytometry.

Histology {#s4-15}
---------

Lung tissues were fixed in formalin solution and coated with wax for sectioning. Sections were stained with Hematoxylin and Eosin (H and E) dyes and slides were scored for granulomas by analyzing under a light microscope.

Antibodies {#s4-16}
----------

We used the following antibodies: CD4-PerCP (100538), CD8-APC/Cy7 (100713), CD69-FITC (104506), CD25-APC (101910), IFNγ-APC (505810), IL17-PE/Cy7 (506922), CD11b-APC/Cy7 (101226), CD11c-APC (117310), CD80-FITC (104706), MHCII-PE (107607), CD3-PacificBlue (100214), CD4-PE (100512), CD4-APC (100516) and CD4-FITC (100510) from Biolegend, USA.

SIRT2 (ab211033), β-actin (ab8227), acH3K18 (ab40888), α-tubulin (ab184613), acetyl-α-tubulin (ab179484), acetyl-NFκB p65 (ab19870), Alexa Fluor 647 (ab150075) and IgG-APC isotype control (ab232814) from Abcam.

ERK1/2 (9102), Phospho-ERK1/2 (9101), p-38 (9212) and phospho-p38 (4511) from Cell Signaling Technology.

Statistical analysis {#s4-17}
--------------------

All mice experiments were done once with five mice per group per time point (n = 5). RNAseq was performed with three biological replicates from each condition. Significant differences were determined by t-test or one-way ANOVA. p\<0.05 indicated statistically significant results.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This work addresses the role of SIRT2 during *Mycobacterium tuberculosis* (*Mtb*) infection and how this can be exploited in new therapeutic approaches. These studies are important for our general understanding of *Mtb* pathogenesis as well as the development of new host-directed therapies.

**Decision letter after peer review:**

Thank you for submitting your article \"Host Sirtuin 2 as an Immunotherapeutic Target against Tuberculosis\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Dominique Soldati-Favre as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, the authors show that *Mtb* modulates NAD^+^ dependent histone deacetylase Sirtuin 2 (SIRT2) resulting in changes in histone acetylation, cellular signaling and transcriptional profile of the infected host macrophages and *Mtb* stimulated T-cells. Pharmacological inhibition of SIRT2 improved infection outcomes in *Mtb*-infected mice. Mice had reduced CFU, improved pathology and exhibited enhanced Th1/Th17 response. This is a nice study, but several key experiments are missing weakening the overall conclusions that inhibition of the SIRT2 pathway in T cells provides a novel therapeutic host target against *Mtb*. A compiled list of reviewer comments are included below, but as a summary, the major concerns that all reviewers agreed on were the manuscript\'s disjointed organization and focus, experiments needed to be repeated for rigor and reproducibility standards, missing key data (i.e. need to show CFU in Figure 10), missing key information on how experiments were performed, and the absence of an experiment demonstrating the role of T cell-specific-SIRT2 inhibition during *Mtb* infection.

Essential revisions:

1\) Figure 10: A key measurement missing in this experiment is CFU. The authors show that the adoptively transferred T cells from SIRT2-deficient mice were polyfunctional. However, whether the adoptive transfer of these T cells affected the bacterial burden in the lungs was not determined. This is important since it is abundantly clear that polyfunctional T cells do not reflect the ability of the T cells to restrict intracellular *Mtb* growth.

2\) Better quality and higher magnification H&E images should be included. Also, it would be helpful in evaluating pathological changes if the low magnification images of the entire lung lobe for all the mice are provided, maybe as supplementary data. Also, histopathological changes should be presented as quantitation of lung inflammation rather than presenting it as the number of granulomas.

3\) Concerns with the flow of the paper, which was slightly disjointed -- it starts with in vitro work showing macrophages are important for the SIRT2 effect, then onto consistent results in a mouse model treated with the same inhibitor then back to showing T cells matter when it turns out that the mouse result is not consistent with previous work. It might be smoother if the authors showed upfront that macrophages and T-cells were involved in altered SIRT2 and then go on to the in vivo results to dissect which aspect has the largest effect in vivo. Further, the authors explain the discrepancy between Cardoso et al., 2015 results (higher CFU early and then no effect by 60 days) being due to the myeloid-specific KO used in the previous study. The drug/inhibitor being used in the current study may indeed show the importance of cells other than myeloid as having a role, however, considering in the current study the authors spent the first few figures arguing for the SIRT2 effect as being specific to macrophages, I find it hard to reconcile the sudden shift in argument that it is independent of macrophages.

4\) To demonstrate a role for T cells in vivo during Sirt2 inhibition, the authors could deplete T-cells in the mouse after infection (+/- inhibitor) to see if the protective effect (of lower CFU burden) is lost without T-cells.

5\) The other hypothesis is that the inhibitor is not just against SIRT2 and may have off-target effects explaining the reduced bacterial growth in mice. This could be tested by having genetic (SIRT2 T cell specific KO mouse) targeting of SIRT2. Without genetic validation to show that the drug is working through Sirt2 specifically and Sirt2\'s important role is in T cells (although it may still be a combination of macs + T cells), the authors must be careful to not overstate their findings without this genetic data.

6\) Figure 1A -- Unclear why only SIRT1 and 2 data was shown, when the claim is that they are significantly upregulated/downregulated from a total of 18 HDACs. Why not show all or at least comment on the others not being altered? Also unclear why there are no error bars to show the variability of induction after infection. Depending on how the data was normalized, it may be hard to show standard deviation, but at least put confidence intervals so the reader can interpret variability.

7\) Figure 1E -- The timepoint for upregulation of SIRT2 expression from 1A was 24 hrs -- in 1B the reduced bacterial growth was at 48 hours. Did the reduced bacterial growth also correlate with a reduction in SIRT2 after drug treatment at 48hours? Could this effect be seen at 24 hours?

8\) Figure 1F -- this is CFU data presented as % survival -- it would be easier to readers to interpret if the average CFU for each replicate was shown instead. Also with Figure 1I.

9\) The RNAseq data in Figure 3 was nice to show the transcriptional landscape of SIRT2 inhibition in cells but I'm not really sure what the difference in 3D and 3E is, except for different ways of showing that immune genes are altered after SIRT2 inhibition. Also unclear why only 3 upregulated and 2 downregulated genes were cherry-picked to validate. Were more checked but didn\'t validate? It might have been nice to validate some of genes of the pathways that were highlighted in D and E.

10\) Considering all of the in vitro and ex vivo work in Figures 1-4 were done in C57BL/6 mice, it is unclear why the study then switched to BALB/c mice for the in vivo experiments (i.e. BALB/c are still relatively resistant to infection but have different H2 haplotypes and immune profiles) and then back to C57BL/6 mice for some of the T-cell coculture experiments. Could the discrepancy with in vivo results and past work simply be due to different host backgrounds being examined in vivo? Can the authors comments on that in the Discussion?

11\) In Figure 8 when infected mouse spleens are immunoprofiled, it is unclear why the authors chose the spleen and not the lung. It has been shown that there are organ-specific differences in protective immunity (Sakai, 2016). Was this experiment back to BALB/c mice again? This should be made clear in the figure legend.

12\) There is no mention in the Introduction that genetic Sirt2 deletion in myeloid cells was shown to increase *Mtb* load in the lungs of mice early but not at later timepoints (Cardoso et al., 2015) or that SIRT2 deficiency enhances bacterial phagocytosis as a mechanism explaining increased survival in chronic staph infection (Ciarlo, 2017). These references are mentioned later in the Results and Discussion when the results are discrepant from previous studies, but it might be nice to mention these on the front to so the reader is aware there has been past work in this area (at the moment, the Introduction seems to be pitched that no one has looked at sirtuins in *Mtb* before).

13\) Some hyperbole throughout manuscript -- for e.g. \"to our astonishment\"; \"brilliant strategies\" could be toned down.

14\) What was the sex of the mice used in vitro and in vivo? Note sex differences have been observed in both human and mouse studies. For the field standard and reproducibility, it would be helpful to include the mouse sex in the Materials and methods.

15\) Several of the in vivo experiments (Figure 8, 9 and 10), the adoptive transfer experiment and splenocyte flow cytometry experiment were only performed once with 3 mice -- for rigor and reproducibility, the authors should repeat these experiments for independent biological replicates.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Host Sirtuin 2 as an Immunotherapeutic Target against Tuberculosis\" for further consideration by *eLife*. Your revised article has been evaluated by Dominique Soldati-Favre (Senior Editor) and a Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

The reviewers all agree that the revised manuscript is greatly improved, and additional data have been provided to mostly address the original concerns. There were just a few remaining points to be addressed and included:

1\) The authors should describe what the control cells are (Figure 10 G and H) in the adoptive transfer experiment. Are they cells from infected but not AGK2 infected mice?

2\) Please add a discussion of the increase in acetylated-tubulin in infected (Cnt) cells compared to uninfected (Cnt) cells and the similar increase in infected (AGK2) cells compared to uninfected (AGK2) cells in Figure 2E.

3\) For Figure 4, Figure 6E-J, please include data from both experiments.

4\) Subsection "SIRT2 deacetylates NFκB p65 in *Mtb* specific T cells", fourth paragraph should be read as -- SIRT2 \"inhibition by AGK2\" modulated the acetylation.

5\) Figure 7 -- There are issues with the gating strategy of the lung APCs. The first gate is labeled as lymphocytes, but that is not an accurate label for that population. In general, how the authors decided on their gates is not clear and does not appear to match the pattern of cells on the plots. The boxes do not contain distinct populations and often cut across populations. Were fluorescence minus one (FMO) controls used to determine where to make the cutoff for each marker? Can authors provide details regarding what they think each population is, in addition to defining the populations based on markers?

6\) Please confirm if the mouse experiments (Figure 7 -- 10) were done more than once, and if they were only done once, please add a replicate experiment.

10.7554/eLife.55415.sa2

Author response

> Essential revisions:
>
> 1\) Figure 10: A key measurement missing in this experiment is CFU. The authors show that the adoptively transferred T cells from SIRT2-deficient mice were polyfunctional. However, whether the adoptive transfer of these T cells affected the bacterial burden in the lungs was not determined. This is important since it is abundantly clear that polyfunctional T cells do not reflect the ability of the T cells to restrict intracellular Mtb growth.

We thank the editor and the reviewers for the insightful comments that have improved both the content and the presentation of our work. We agree with the reviewers. To investigate whether the T cells isolated from AGK2 treated infected animals transfer protective immunity against *Mtb*, CD4^+^ and CD8^+^ T cells from control and AGK2 treated infected mice were transferred into naive immuno-deficient *Rag1^-/-^* mice followed by low dose infection (\~110 CFU/lung) with aerosolized *Mtb* and CFU enumeration after 21 days post infection. T cells from AGK2 treated animals were more efficient in imparting protection to the *Rag1^-/-^* mice. The data is provided in Figure 10G and H.

> 2\) Better quality and higher magnification H&E images should be included. Also, it would be helpful in evaluating pathological changes if the low magnification images of the entire lung lobe for all the mice are provided, maybe as supplementary data. Also, histopathological changes should be presented as quantitation of lung inflammation rather than presenting it as the number of granulomas.

We thank the reviewers for the comments. In the revised manuscript, we have included the representative 10X, 20X and 40X magnification images of the lungs (Figure 6B). The quantification of the lung inflammation is done in accordance with the previous literature (Soni et al., 2015). The table describing the number and nature of granulomas has now been included in the manuscript (Figure 6C).

> 3\) Concerns with the flow of the paper, which was slightly disjointed -- it starts with in vitro work showing macrophages are important for the SIRT2 effect, then onto consistent results in a mouse model treated with the same inhibitor then back to showing T cells matter when it turns out that the mouse result is not consistent with previous work. It might be smoother if the authors showed upfront that macrophages and T-cells were involved in altered SIRT2 and then go on to the in vivo results to dissect which aspect has the largest effect in vivo. Further, the authors explain the discrepancy between Cardoso et al., 2015 results (higher CFU early and then no effect by 60 days) being due to the myeloid-specific KO used in the previous study. The drug/inhibitor being used in the current study may indeed show the importance of cells other than myeloid as having a role, however, considering in the current study the authors spent the first few figures arguing for the SIRT2 effect as being specific to macrophages, I find it hard to reconcile the sudden shift in argument that it is independent of macrophages.

We appreciate the comments concerning the flow of the manuscript. In the revised manuscript we have reorganized the figures in order to segregate the ex vivo and in vivo work more effectively.

We agree with the reviewers that the first two figures of the manuscript describe the importance of SIRT2 inhibition in macrophages in restricting intracellular bacterial growth. Our rationale behind starting the manuscript with the macrophage infection experiments was based on the fact that the macrophages are one of the very first cells to encounter *Mtb* inside the host. The transcriptome analysis of macrophages following *Mtb* infection and SIRT2 inhibition revealed important insights into a plausible role of SIRT2 in modulating T cell responses during *Mtb* infection and hence we went further to investigate the T cell mediated responses after SIRT2 inhibition.

We do concur that our ex vivo and in vivo results do not follow the same trend as described by Cardoso et al. in 2015 where myeloid-specific SIRT2 KO mice displayed higher bacterial burden at early time points with no effect at 60 days post infection. To address this disparity, we hypothesized that it is the inhibition of SIRT2 in cells other than macrophages is critical for containing the *Mtb* infection. To validate the hypothesis, we performed experiments in *Rag1^-/-^* mice that lack mature B and T cells. AGK2 treatment in these immuno-deficient mice did not alter the bacterial survival as compared to the control group (Figure 6H-J) indicating that SIRT2 inhibition in T cells is important to restrict *Mtb* growth inside the host. However, since macrophages are essential for activating T cell mediated immunity, we do not believe that the phenotype is independent of macrophages.

> 4\) To demonstrate a role for T cells in vivo during Sirt2 inhibition, the authors could deplete T-cells in the mouse after infection (+/- inhibitor) to see if the protective effect (of lower CFU burden) is lost without T-cells.

We would like to thank the reviewers for their suggestion. To demonstrate the importance of SIRT2 inhibition in T cells, we used *Rag1^-/-^* mice which lack mature T cells. As discussed in the previous response, the effect of AGK2 treatment in terms of reduced bacterial survival is lost in these immuno-deficient mice (Figure 6H-J) indicating that inhibition of SIRT2 in T cells is important to restrict *Mtb* growth inside the host.

> 5\) The other hypothesis is that the inhibitor is not just against SIRT2 and may have off-target effects explaining the reduced bacterial growth in mice. This could be tested by having genetic (SIRT2 T cell specific KO mouse) targeting of SIRT2. Without genetic validation to show that the drug is working through Sirt2 specifically and Sirt2\'s important role is in T cells (although it may still be a combination of macs + T cells), the authors must be careful to not overstate their findings without this genetic data.

We completely agree with the reviewers on the possible unknown off-target effects of AGK2. The experiments in *Rag1^-/-^* mice (Figure 6H-J) to an extent suggest that the observed phenotype is likely not due to do the off-target effects of AGK2. Nonetheless, we agree that in the absence of genetic validation, we should be careful not to overstate the findings. Thus, we have avoided making any overstatements in the revised manuscript.

> 6\) Figure 1A -- Unclear why only SIRT1 and 2 data was shown, when the claim is that they are significantly upregulated/downregulated from a total of 18 HDACs. Why not show all or at least comment on the others not being altered? Also unclear why there are no error bars to show the variability of induction after infection. Depending on how the data was normalized, it may be hard to show standard deviation, but at least put confidence intervals so the reader can interpret variability.

We would like to apologize for not commenting on all the HDACs. In the revised manuscript, bar graph in Figure 1A is replaced by a table detailing the expression of all the HDACs which are significantly altered in THP1 cells at 24h post infection (SIRT1, SIRT2, HDAC6 and HDAC9). The data was analysed with the help of GEO2R (Gene Expression Omnibus series accession number GSE65714).

> 7\) Figure 1E -- The timepoint for upregulation of SIRT2 expression from 1A was 24 hrs -- in 1B the reduced bacterial growth was at 48 hours. Did the reduced bacterial growth also correlate with a reduction in SIRT2 after drug treatment at 48hours? Could this effect be seen at 24 hours?

AGK2 is a specific and a reversible inhibitor of SIRT2 activity. It is known that AGK2 targets the nicotinamide binding site of SIRT2 (Outeiro et al., 2007). However, our data suggests that AGK2 treatment during *Mtb* infection also leads to the reduction of SIRT2 mRNA levels. We believe that the reduced bacterial survival after 48h of AGK2 treatment is because of the inhibition of SIRT2 activity as well as a reduction in SIRT2 levels. Similar mycobacterial growth restriction was observed as early as 24h post treatment with AGK2. The data is provided in Figure 1E.

> 8\) Figure 1F -- this is CFU data presented as % survival -- it would be easier to readers to interpret if the average CFU for each replicate was shown instead. Also with Figure 1I.

The CFU data was presented as % survival wrt the 0h time point to negate the effect of any variation in the uptake of the bacilli due to the pre-treatment with AGK2. In the revised manuscript, the data in Figure 1F and 1I has been replaced by the average CFU for each replicate at 0h and 48h post infection.

> 9\) The RNAseq data in Figure 3 was nice to show the transcriptional landscape of SIRT2 inhibition in cells but I'm not really sure what the difference in 3D and 3E is, except for different ways of showing that immune genes are altered after SIRT2 inhibition. Also unclear why only 3 upregulated and 2 downregulated genes were cherry-picked to validate. Were more checked but didn\'t validate? It might have been nice to validate some of genes of the pathways that were highlighted in D and E.

We have rearranged the figure. Earlier Figure 3D depicted the KEGG pathway analysis of all the SIRT2 dependent genes whereas Figure 3E represented the gene ontology immune system analysis on SIRT2 dependent upregulated genes. However, to avoid confusion we have removed Figure 3E in the revised version. We have also included RT-PCR on the candidate genes which belong to key pathways such as antigen presentation and processing, Th17 differentiation, T cell activation, NFκB signalling and PI3K-Akt signalling (Figure 3D and 3E).

> 10\) Considering all of the in vitro and ex vivo work in Figures 1-4 were done in C57BL/6 mice, it is unclear why the study then switched to BALB/c mice for the in vivo experiments (i.e. BALB/c are still relatively resistant to infection but have different H2 haplotypes and immune profiles) and then back to C57BL/6 mice for some of the T-cell coculture experiments. Could the discrepancy with in vivo results and past work simply be due to different host backgrounds being examined in vivo? Can the authors comments on that in the Discussion?

We thank the reviewers for the comments. In order to maintain the consistency in the ex vivo and in vivo work, we have now repeated the in vivo experiments in C57BL/6 mice. The *Rag1^-/-^* mice used in the study are also in C57BL/6 background.

> 11\) In Figure 8 when infected mouse spleens are immunoprofiled, it is unclear why the authors chose the spleen and not the lung. It has been shown that there are organ-specific differences in protective immunity (Sakai, 2016). Was this experiment back to BALB/c mice again? This should be made clear in the figure legend.

To address the concern, we have included the immune profiling data of the lungs of infected C57BL/6 mice (Figure 7A-E, Figure 8A-G and Figure 9A-G) in the revised manuscript.

> 12\) There is no mention in the Introduction that genetic Sirt2 deletion in myeloid cells was shown to increase Mtb load in the lungs of mice early but not at later timepoints (Cardoso et al., 2015) or that SIRT2 deficiency enhances bacterial phagocytosis as a mechanism explaining increased survival in chronic staph infection (Ciarlo, 2017). These references are mentioned later in the Results and Discussion when the results are discrepant from previous studies, but it might be nice to mention these on the front to so the reader is aware there has been past work in this area (at the moment, the Introduction seems to be pitched that no one has looked at sirtuins in Mtb before).

We thank the reviewers for the insight. In the revised manuscript, we have modified the Introduction by adding these references and a few more which talk about sirtuins and HDACs during bacterial infections.

> 13\) Some hyperbole throughout manuscript -- for e.g. \"to our astonishment\"; \"brilliant strategies\" could be toned down.

We appreciate the reviewer's concerns. The point is well noted, and necessary changes have been made.

> 14\) What was the sex of the mice used in vitro and in vivo? Note sex differences have been observed in both human and mouse studies. For the field standard and reproducibility, it would be helpful to include the mouse sex in the Materials and methods.

In the revised manuscript, we have included the details about the sex of mice used in the ex vivo and in vivo studies.

> 15\) Several of the in vivo experiments (Figure 8, 9 and 10), the adoptive transfer experiment and splenocyte flow cytometry experiment were only performed once with 3 mice -- for rigor and reproducibility, the authors should repeat these experiments for independent biological replicates.

We have repeated these experiments in C57BL/6 mice (5 mice per group).

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

> \[...\]
>
> 1\) The authors should describe what the control cells are (Figure 10 G and H) in the adoptive transfer experiment. Are they cells from infected but not AGK2 infected mice?

The control cells (Cnt) in Figure 10G and 10H represent the T cells isolated from *Mtb* infected animals which were not treated with AGK2 while AGK2 represents the cells isolated from *Mtb* infected and AGK2 treated mice. We have added this information in the Results section of the revised manuscript.

> 2\) Please add a discussion of the increase in acetylated-tubulin in infected (Cnt) cells compared to uninfected (Cnt) cells and the similar increase in infected (AGK2) cells compared to uninfected (AGK2) cells in Figure 2 E.

There is enhanced nuclear localization of SIRT2 during *Mtb* infection which leaves very little protein in the cytosol and as a result there is an overall increase in the acetylated-tubulin levels in *Mtb* infected cells as compared to the uninfected macrophages. We have added this discussion in the Results section of the revised manuscript.

> 3\) For Figure 4, Figure 6E-J, please include data from both experiments.

The figures in the revised version include the data from both the experiments.

> 4\) Subsection "SIRT2 deacetylates NFκB p65 in Mtb specific T cells", fourth paragraph should be read as -- SIRT2 \"inhibition by AGK2\" modulated the acetylation.

We have made the asked changes in the revised manuscript.

> 5\) Figure 7 -- There are issues with the gating strategy of the lung APCs. The first gate is labeled as lymphocytes, but that is not an accurate label for that population. In general, how the authors decided on their gates is not clear and does not appear to match the pattern of cells on the plots. The boxes do not contain distinct populations and often cut across populations. Were fluorescence minus one (FMO) controls used to determine where to make the cutoff for each marker? Can authors provide details regarding what they think each population is, in addition to defining the populations based on markers?

We would like to thank the reviewers for their insights. We would like to apologize for the mislabelling of the population in dot plot. By default, FlowJo software names the first population to be gated as lymphocytes. In the revised version, we have changed the name of the first gate in Figure 7-9. Since in Figure 7-9, we are analysing the total lung and spleen cells, the first gate was decided based on the distinct population by adjusting FSC and SSC voltages followed by doublet exclusion gates. Yes, we use FMO controls for the gating. We also use unstained and single colour controls to apply the gates over the population wherever it is necessary. Further, we make use of contour plots to mark the populations whenever they are not clearly distinct in the dot plots. Finally, we apply the same gates across the samples to be analysed.

> 6\) Please confirm if the mouse experiments (Figure 7 -- 10) were done more than once, and if they were only done once, please add a replicate experiment.

Yes, the mice experiments in Figure 6-10 were done more than once. The CFU data from two biological replicates have been added in Figure 6E-J and Figure 10H. We apologize for not including the biological replicate in the earlier version.
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